<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00975325</url>
  </required_header>
  <id_info>
    <org_study_id>YOH-BE-2009</org_study_id>
    <secondary_id>EudraCT No.2009-013122-16</secondary_id>
    <nct_id>NCT00975325</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine</brief_title>
  <official_title>Characterisation of Relative Bioavailability and Assessment of Bioequivalence of Two Generic Yohimbine Formulations in Comparison With a Marketed Reference Product - an Open, Randomised, Single Dose, 3-period Change-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Ritter GmbH &amp; Co</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walter Ritter GmbH &amp; Co</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Type: Bioequivalence study in male healthy volunteers, therapeutical indication&#xD;
           (erectile disfunction) not studied&#xD;
&#xD;
        -  Products, dosage, and route of administration:&#xD;
&#xD;
             -  Test 1: Yohimbin &quot;Spiegel&quot;® (Desma GmbH, Germany), tablet containing 5 mg yohimbine&#xD;
                hydrochloride, oral administration&#xD;
&#xD;
             -  Reference: Yocon-Glenwood® (Glenwood GmbH, Germany), tablet containing 5 mg&#xD;
                yohimbine hydrochloride, oral administration&#xD;
&#xD;
        -  Duration of treatment:&#xD;
&#xD;
           2 single-dose administrations of 5 mg yohimbine hydrochloride each under fasting&#xD;
           conditions separated by a wash-out period of at least one week i.e. 6 treatment free&#xD;
           days between all administrations&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study objectives&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
        -  Characterisation of relative bioavailability of Test 1 in comparison to Reference after&#xD;
           single dose administration under fasting conditions&#xD;
&#xD;
        -  Assessment of bioequivalence of Test 1 vs. Reference after single dose administration&#xD;
           under fasting conditions, determined by use of area under the concentration time curve&#xD;
           AUC0-tlast and maximal concentration Cmax obtained for yohimbine&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
        -  Descriptive characterisation of safety and tolerability of the investigational products&#xD;
           in the study population&#xD;
&#xD;
        -  Descriptive characterisation of blood pressure and pulse rate around Cmax of the&#xD;
           investigational products in the study population&#xD;
&#xD;
      Analytical methodology:&#xD;
&#xD;
      Yohimbine in plasma samples will be analysed by use of a validated HPLC-MS/MS; intended LLOQ&#xD;
      for yohimbine is 0.5 ng/ml&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameter AUC, Cmax</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Yohimbine, Yohimbine &quot;Spiegel&quot;</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Yohimbine Yocon-Glenwood</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yohimbine</intervention_name>
    <description>yohimbine 5 mg, one tablet, single dose only</description>
    <arm_group_label>Yohimbine, Yohimbine &quot;Spiegel&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yohimbine</intervention_name>
    <description>yohimbine 5 mg, one tablet, single dose only</description>
    <arm_group_label>Yohimbine Yocon-Glenwood</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sex: male&#xD;
&#xD;
          -  Ethnic origin: Caucasian&#xD;
&#xD;
          -  Age: 18 - 55 years, inclusive&#xD;
&#xD;
          -  Body-mass index1 (BMI): ≥ 19 kg/m² and ≤ 27 kg/m²&#xD;
&#xD;
          -  Good state of health&#xD;
&#xD;
          -  Non-smoker or an ex-smoker for a least 1 month&#xD;
&#xD;
          -  Written informed consent, after having been informed about benefits and potential&#xD;
             risks of the trial, as well as details of the insurance taken out to cover the&#xD;
             subjects participating in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Safety concerns:&#xD;
&#xD;
               1. Existing cardiac or haematological diseases and/or pathological findings, which&#xD;
                  might interfere with the safety, tolerability, absorption and/or pharmacokinetics&#xD;
                  of the active ingredient&#xD;
&#xD;
               2. Existing hepatic and/or renal diseases and/or pathological findings, which might&#xD;
                  interfere with the safety, tolerability, absorption and/or pharmacokinetics of&#xD;
                  the active ingredient&#xD;
&#xD;
               3. Existing gastrointestinal diseases and/or pathological findings, which might&#xD;
                  interfere with the safety, tolerability, absorption and/or pharmacokinetics of&#xD;
                  the active ingredient&#xD;
&#xD;
               4. History of relevant CNS and/or psychiatric disorders and/or currently treated CNS&#xD;
                  and/or psychiatric disorders&#xD;
&#xD;
               5. Pathological ECG (12 standard leads) which might interfere with the safety of the&#xD;
                  active ingredient&#xD;
&#xD;
               6. Known allergic reactions to the active ingredients used or to constituents of the&#xD;
                  pharmaceutical preparations&#xD;
&#xD;
               7. Subjects with severe allergies or multiple drug allergies&#xD;
&#xD;
               8. Systolic blood pressure &lt;100/&gt;140 mmHg&#xD;
&#xD;
               9. Diastolic blood pressure &lt;60/&gt;90 mmHg&#xD;
&#xD;
              10. Pulse rate &lt;45/&gt;110 bpm&#xD;
&#xD;
              11. Laboratory values out of normal range unless the deviation from normal is judged&#xD;
                  as not relevant for the study by the investigator&#xD;
&#xD;
              12. Positive anti-HIV-test, HBs-AG-test or anti-HCV-test&#xD;
&#xD;
              13. History of glaucoma&#xD;
&#xD;
          -  Lack of suitability for the trial 14. Subjects exhibiting extreme genetic polymorphism&#xD;
             of CYP 2D6 - &quot;Poor or Ultra-rapid metabolizer&quot; 15. Acute or chronic diseases which&#xD;
             could affect absorption or metabolism 16. History of or current drug or alcohol&#xD;
             dependence 17. Regular intake of alcoholic food or beverages of ≥ 40 g pure ethanol&#xD;
             for male per day 18. Subjects who are on a diet which could affect the&#xD;
             pharmacokinetics of the active ingredient 19. Regular intake of caffeine containing&#xD;
             food or beverages of ≥ 500 mg per day 20. Blood donation or other blood loss of more&#xD;
             than 400 ml within the last two months prior to individual enrolment of the subject&#xD;
             21. Participation in a clinical trial during the last two months prior to individual&#xD;
             enrolment of the subject 22. Regular treatment with any systemically available&#xD;
             medication (except continuous usual replacement therapy e.g. L-thyroxine) within two&#xD;
             weeks prior to the first administration of the study medication 23. Intake of&#xD;
             yohimbine for any reason (e.g. fat burning, weight reduction, muscle improvement, post&#xD;
             operative care and/or any therapy for erectile dysfunctions) within two weeks prior to&#xD;
             first administration of the study medication 24. Subjects, who report a frequent&#xD;
             occurrence of migraine attacks&#xD;
&#xD;
          -  Administrative reasons 25. Subjects suspected or known not to follow instructions 26.&#xD;
             Subjects who are unable to understand the written and verbal instructions, in&#xD;
             particular regarding the risks and inconveniences they will be exposed to during their&#xD;
             participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Donath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SocraTec R&amp;D GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SocraTec R&amp;D GmbH</name>
      <address>
        <city>Erfurt</city>
        <zip>D-99084</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>September 8, 2009</study_first_submitted>
  <study_first_submitted_qc>September 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2009</study_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Yohimbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

